KR101890017B1 - Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients - Google Patents
Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients Download PDFInfo
- Publication number
- KR101890017B1 KR101890017B1 KR1020150149647A KR20150149647A KR101890017B1 KR 101890017 B1 KR101890017 B1 KR 101890017B1 KR 1020150149647 A KR1020150149647 A KR 1020150149647A KR 20150149647 A KR20150149647 A KR 20150149647A KR 101890017 B1 KR101890017 B1 KR 101890017B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- present
- preventing
- gold
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 244000050053 Rosa multiflora Species 0.000 title claims description 11
- 235000000656 Rosa multiflora Nutrition 0.000 title claims description 11
- 240000004534 Scutellaria baicalensis Species 0.000 title claims description 7
- 235000017089 Scutellaria baicalensis Nutrition 0.000 title claims description 7
- 208000026278 immune system disease Diseases 0.000 title abstract description 21
- 230000001404 mediated effect Effects 0.000 title abstract description 20
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000010931 gold Substances 0.000 claims abstract description 30
- 229910052737 gold Inorganic materials 0.000 claims abstract description 30
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- 230000024245 cell differentiation Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 239000005445 natural material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 12
- 229940092253 ovalbumin Drugs 0.000 description 12
- 239000006210 lotion Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 240000008397 Ganoderma lucidum Species 0.000 description 8
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 8
- -1 IL- 6 Proteins 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229940109850 royal jelly Drugs 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
- 241000207929 Scutellaria Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 235000006595 Roystonea elata Nutrition 0.000 description 3
- 244000126647 Roystonea oleracea Species 0.000 description 3
- 235000008947 Roystonea oleracea Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- AIVAIDWKSMJVED-UHFFFAOYSA-N 2,3,3-trimethyl-2-propylnonanoic acid Chemical compound CCCCCCC(C)(C)C(C)(CCC)C(=O)O AIVAIDWKSMJVED-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- GEAXBDGHFPKTBK-UHFFFAOYSA-N C(C)C1=C(C(OCCC(O)O)=O)C=CC(=C1)O Chemical compound C(C)C1=C(C(OCCC(O)O)=O)C=CC(=C1)O GEAXBDGHFPKTBK-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DEUFHLFQPMURDV-UHFFFAOYSA-N Dimethoxycinnamic acid Chemical compound COC(C(O)=O)=C(OC)C1=CC=CC=C1 DEUFHLFQPMURDV-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100459248 Mus musculus Mxra8 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000703174 Teleuscolex baicalensis Species 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000013184 negative regulation of T cell differentiation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for preventing, ameliorating, or treating a Th2-mediated immune disease, which comprises an actinic and gold extract as an active ingredient. Since the spirit room and the gold are a natural material which provides little cost and low production cost and convenience of use, the composition comprising the spirit room and the golden extract as an active ingredient is a therapeutic agent for preventing, improving or treating a Th2- Health functional foods, and cosmetics.
Description
The present invention relates to a composition for preventing, ameliorating, or treating a Th2-mediated immune disease, which comprises an actinic and gold extract as an active ingredient.
Environmental factors such as environmental pollution, westernization of diet and lifestyle, and allergies caused by environmental factors, heredity and various allergens are increasing worldwide prevalence, and 20 ~ 25% , Asthma, atopic dermatitis, and food allergies.
Allergies are a malfunction of the immune system, and substances that do not have a significant effect on normal people cause hypersensitivity reactions such as urticaria, itching, runny nose, and cough. Allergic reactions are traditionally divided into four classes based on the time and type of expression: type I-type III is a humoral immune response (immediate type) involving antibodies, type IV is a cell-mediated immune response Delay type). Most allergic reactions are type I, and are typical diseases such as asthma, rhinitis, conjunctivitis, food and drug allergy, and atopic dermatitis. In severe cases, anaphylaxis may occur.
Type I immediate-type hypersensitivity is divided into two stages. In the first stage, IL-12, which suppresses the secretion of IgE and IgG1 by the invasion of allergen, increases the secretion of IgG2a, and Th1 (
The second stage of the allergic manifestation is divided into an initial reaction and a late reaction. In the initial reaction, the allergen re-enters the body to stimulate mast cells and induce a degranulation reaction. At this time, vasodilation by histamine, lipid metabolites, cytokines, And late response is activated by infiltration of neutrophils, eosinophils, macrophages, Th2 cells, basophils, and the like in the tissues, thereby causing inflammation and causing atopic dermatitis, rhinitis and asthma. Among these degranulation secretions, histamine is the most well-known factor and is also used as an important indicator of allergic symptoms in relation to immediate hypersensitivity reaction.
Currently, most medicines for the treatment of allergy are focused on suppressing the secretion of histamine secreted in the last stage of the allergy mechanism or treating the symptoms caused by allergy, and there are few therapeutic agents showing definite effects. The treatment of allergic diseases can be done for a long period of time. Most of the drugs with excellent therapeutic effect are widely used for atopic dermatitis, allergic rhinitis and asthma as long as they are steroid drugs. However, long term use can cause serious side effects. Antihistamines also cause symptoms to feel alleviated, but long-term use causes side effects such as depression, concentration difficulties, lethargy, drowsiness, and hepatic disorders, and the problem of recurrence of allergic diseases is discontinued. In addition, since allergic diseases, especially atopic dermatitis, are mostly in children and adolescents, it is very important to develop a safe therapeutic agent free from toxicity and side effects, and studies to overcome these limitations have been actively carried out, It is not. Accordingly, there is a growing need for the development of safe functional foods which can reduce the dose of these drugs and replace them to some extent, and have no side effects for long-term treatment.
Therefore, in order to develop therapeutic agents and functional foods that can cope with allergies and have no toxicity and side effects, it is necessary to actively develop materials having safety and certain efficacy from natural products and foods.
On the other hand, Rosa multiflora is a fruit of a briar that grows widely in Korea and Japan. It is spherical or elliptical, its outer surface is reddish or dark reddish brown, and the tip of the fruit has a pentagonal stigma. It has a slightly sour smell, a little taste, it does not see urine easily, it is used for edema, insomnia, sexual decline, boils, malt, promotes blood circulation and removes poison. In addition, pharmacological actions such as coronary artery dilation, prolonged mouse life, lipid, protein metabolism improving action, and atherosclerosis formation inhibitory action have been reported.
Golden ( Scutellaria baicalensis ) is the root of the blooming grass and is distributed in grassland of Korea, China, Mongolia, and eastern Siberia. Conical shape, twisted and curved, yellowish brown to dark yellow on the outside, little odor, slightly tasteless. In oriental medicine, it is used as fever, diuretic, branch, insect, and anti-inflammatory, and is grown as medicinal plant.
The inventors of the present invention have conducted studies to evaluate the inhibitory effect of Th2-mediated immune diseases by the mixture treatment of the above-mentioned Young Sil and gold extract, and have completed the present invention based thereon.
The inventors of the present invention completed the present invention on the basis of confirming the Th2 immune response and T cell differentiation inhibitory effect of treating the mouse spleen cells immunized with OVA antigen.
Accordingly, it is an object of the present invention to provide a composition for preventing, ameliorating, or treating a Th2-mediated immune disorder, which comprises an actinic and gold extract as an active ingredient.
However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
In order to accomplish the object of the present invention as described above, the present invention relates to a method of producing Rosa multiflora and golden ( Scutellaria) The present invention also provides a pharmaceutical composition for preventing or treating a Th2-mediated immune disease.
In addition, the present invention relates to a composition comprising Rosa multiflora and Golden ( Scutellaria) The present invention provides a health functional food composition for preventing or ameliorating a Th2-mediated immune disease.
In addition, the present invention relates to a composition comprising Rosa multiflora and Golden ( Scutellaria) The present invention also provides a cosmetic composition for prevention or improvement of a Th2-mediated immune disorder, which comprises an extract of Baikalensis as an active ingredient.
In one embodiment of the present invention, the Th2-mediated immune disease may be an allergic disease.
In another embodiment of the present invention, the extract is selected from the group consisting of water, C 1 to C 4 lower alcohols, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, It may have been extracted with the selected solvent.
In another embodiment of the present invention, the composition may inhibit the production of IL-4.
In another embodiment of the present invention, the composition can inhibit the differentiation of T cells.
The present invention also provides a method of preventing or treating a Th2-mediated immune disease, comprising administering the composition to a subject.
The present invention also provides the use of the composition for the prevention or treatment of a Th2-mediated immune disorder.
The inventors of the present invention found that when the splenocytes of mice immunized with OVA were mixed with the Ganoderma lucidum and the Ganoderma lucidum extract, the IL-4 secretion inhibitory activity and the T cell differentiation inhibitory activity were markedly enhanced . In addition, since the spirit and gold are natural materials that provide little production cost and ease of use, they have little or no side effects, and compositions containing the spiritual and golden extracts as active ingredients are useful for the prevention, improvement, or treatment of Th2- Therapeutic agents, health functional foods, and cosmetics.
FIG. 1 is a graph showing the results of the measurement of the amount of IL-4 secreted by Th2 in the cell culture after ELISA, gold extract, or royal jelly extract and gold extract were mixed with the splenocytes isolated from mice immunized with OVA Results.
FIG. 2 shows the result of measuring the degree of differentiation of T cells by performing MTT assay on the spleen cells obtained by mixing the spleen cells isolated from mice immunized with OVA with the mixture of Ganoderma extract, Golden extract, to be.
The inventors of the present invention have completed the present invention by confirming that the mixing treatment of the royal jelly extract and the gold extract enhances the Th2 immunosuppressive activity and the T cell differentiation inhibitory activity as compared with the single treatment of the extract.
Accordingly, the present invention relates to a method for producing Rosa multiflora and golden ( Scutellaria) The present invention provides a pharmaceutical composition for the prevention or treatment of a Th2-mediated immune disorder comprising an extract of T. baicalensis as an active ingredient.
As used herein, the term " prophylactic " means any action that inhibits or delays the development of a Th2-mediated immune disorder by administration of a pharmaceutical composition according to the present invention.
As used herein, the term " treatment " means any action that improves or alters the symptoms of a Th2-mediated immune disorder by administering the pharmaceutical composition of the present invention.
As used herein, the term " T cell " refers to a cell that expresses IL-4, IL-5, IL- 6, IL-10, and IL-13. It is known that Th1 / Th2 balance, which is regulated by the cytokines produced by Th1 and Th2 cells, is important for the regulation of cellular immunity and Th2 cells play an important role in the regulation of humoral immunity have. In the normal state, the cytokine, which is important for the differentiation of Th1, is interfering with the cytokine mainly composed of IFN-γ and IL-4, which is important for differentiation of Th2, and the Thl / Th2 balance is kept constant. However, when the Th1 / Th2 balance is broken, various immune diseases can be induced. In the case of deflecting Thl, the cellular immunity is revived to increase the resistance to infection. When the Th2 is deflected, the infection resistance decreases. Conversely, do.
The term " Th2-mediated immune disease ", which is a disease targeted by the present invention, refers to a disease in which IgE and mast cells are involved in the production and activity of allergens, particularly Th2 cells. Examples of such diseases include allergies, Skin diseases including dermatitis, acute and chronic allergic rhinitis, asthma, food allergies, and the like.
The spiritual and gold extracts of the present invention can be extracted using conventional solvents known in the art for extracting extracts from natural products, that is, under the conditions of ordinary temperature and pressure. For example, in the present invention, the spiritual and gold extracts are selected from the group consisting of water, 1 to 4 carbon atoms, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, It can be extracted using more than two kinds of solvents. In addition, the method for extracting the extract from the royal palm and the gold can be extracted through various methods such as room temperature extraction, hot water extraction, cold extraction, reflux extraction, and ultrasonic extraction, but is not limited thereto.
The extract thus prepared may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying. For example, the filtration can be performed using a filter paper or a vacuum filter, the concentration can be carried out using a vacuum concentrator, and the lyophilization can be carried out, but the present invention is not limited thereto.
Further, the extract extracted with the solvent may be further fractionated with a solvent selected from the group consisting of butanol, hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and a mixed solvent thereof. The fractionation temperature may be 4 캜 to 120 캜, but is not limited thereto.
The composition of the present invention can inhibit the production of IL-4.
The composition of the present invention can inhibit the differentiation of T cells.
In the examples of the present invention, experiments were conducted to confirm the improvement or therapeutic effect of Th2-mediated immune diseases on the royal jelly and gold extracts.
In one embodiment of the present invention, when the splenocytes isolated from OVA immunized mice were treated with a mixture of OVA and either a single extract of either the true or golden or golden extract, The amount of IL-4 produced in the culture medium was significantly reduced compared with the case where the culture medium was used (see Example 2). From the above results, it was found that the mixing treatment of royal jelly and gold extract enhances the immune response inhibitory activity by Th2.
In another embodiment of the present invention, MTT assay was performed on spleen cells treated with each of the above extracts. As a result, it was confirmed that when the mixture of Ganoderma lucidum and Golden extract was treated, the T cell differentiation inhibitory activity was enhanced See Example 3).
The pharmaceutical composition according to the present invention may further comprise a pharmacologically acceptable carrier, wherein the pharmaceutical composition comprises a spiritual and a gold extract as an active ingredient. Such pharmaceutically acceptable carriers are those conventionally used in the field of application and include, but are not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, And may further contain other conventional additives such as antioxidants and buffers as needed. In addition, it can be formulated into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like by additionally adding diluents, dispersants, surfactants, binders, lubricants and the like. Suitable pharmaceutically acceptable carriers and formulations can be suitably formulated according to the respective ingredients using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA. The pharmaceutical composition of the present invention is not particularly limited to a formulation, but may be formulated into injections, inhalants, external skin preparations, and the like.
The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may vary depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.
The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, " pharmaceutically effective amount " means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. The effective dose level is determined depending on the type of disease, severity, The time of administration, the route of administration and the rate of excretion, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, the degree of absorption of the active ingredient in the body, the rate of inactivation and the excretion rate, the type of disease, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or one to three divided doses per day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
In another aspect of the present invention, there is provided a health functional food composition for preventing or ameliorating a Th2-mediated immune disease comprising Rosa multiflor a and gold extract ( Scutellaria baicalensis ) as an active ingredient.
As used herein, the term "improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated. Herein, the health functional food composition may be used simultaneously or separately with the medicament for treatment before or after the onset of the disease for the prevention or improvement of the Th2-mediated immune disease.
The term " health functional food composition " as used in the present invention means a food composition comprising at least one of a carrier, diluent, excipient, and additives, selected from the group consisting of tablets, pills, powders, granules, powders, capsules, Which is characterized in that it is formulated into one. Examples of foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, drinks, gums, tea, vitamin complexes, and health functional foods. Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from the group consisting of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and fats can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As the above-mentioned flavors, natural flavors (tautatin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used. The composition according to the present invention can be used in various forms such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies, factic acid and its salts, alginic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. Other compositions according to the present invention may contain flesh for the production of natural fruit juices and vegetable drinks . These components may be used independently or in combination. Specific examples of the carrier, excipient, diluent, and additive include, but are not limited to, lactose, dextrose But are not limited to, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylquilolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water , At least one selected from the group consisting of sugar syrup, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil is preferably used.
In another aspect of the present invention, the present invention provides a cosmetic composition for preventing or ameliorating a Th2-mediated immune disease comprising Rosa multiflora and Scutellaria baicalensis extract as an active ingredient.
The cosmetic composition of the present invention may contain components commonly used in cosmetic compositions as well as spirit chambers and gold extracts and may contain conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and perfumes, And may include a carrier.
In addition, the composition of the present invention may be used in combination with a conventional ultraviolet screening agent as long as it does not impair the skin protecting effect by reacting with the royal palm and the gold extract, in addition to the royal palm and golden extract. Examples of the organic UV blocking agent include glyceryl paraben, drometrizol trisiloxane, drometrizol, dipaloyyl triolate, disodium phenyldibenzimidazole tetrasulfonate, diethylhexylbutamidotriazone, diethylamino Hydroxybenzoylhexyl benzoate, di-methoxycinnamate, a mixture of Rawson and dihydroxyacetone, methylene bis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthyl anthranylate, benzophenone (Benzophenone-4), benzophenone-8 (dioxyphenylbenzone), butylmethoxydibenzoylmethane, bisethylhexyloxyphenol methoxyphenyltriazine, synoxate, ethyl dihydroxypropylparaben, Ethylhexyldimethylpivalate, ethylhexylmethoxycinnamate, ethylhexylsalicylate, ethylhexyltriazone, isoamyl-p-methoxy cinnamate, polysilicon-15 (dimethicodimethylbenzalmate, At least one selected from the group consisting of terephthalylidene dicam peresophilic acid and its salts, thiai-salicylate and aminobenzoic acid (parabe) can be used.
Examples of products to which the cosmetic composition of the present invention can be added include cosmetics such as astringent lotion, softening longevity lotion, nutrition lotion, various creams, essences, packs, foundation and the like, cleansing, cleanser, soap, . Specific formulations of the cosmetic composition of the present invention include skin lotions, skin softeners, skin toners, astringents, lotions, milk lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, moisturizing creams, hand creams, essences, It includes formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, latex, lipstick, makeup base, foundation, press powder, loose powder, eye shadow and the like.
According to a preferred embodiment of the present invention, the content of the spirit and golden extract of the present invention is 0.00001-30% by weight, preferably 0.5-20% by weight, more preferably 1.0-10% by weight, to be. If the content of the spiritual and gold extracts is less than 0.00001% by weight, the effect of absorbing ultraviolet rays is greatly reduced. If the content is more than 30% by weight, skin irritation may be caused.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.
[Example]
Example 1. Preparation and method of experiment
1-1. Preparation of Young Silil Extract
100 g of Rosa multiflora powder and 1 L of alcohol (95% ethanol) were placed in a 2 L glass bottle, shaken in a shaking water bath and shaken for 15 hours at 25 ° C with shaking at 45 rpm. The extract was filtered under reduced pressure using a filter paper, and 100 ml of distilled water was added to wash the remaining spirit residue, followed by filtration under reduced pressure. The filtered extracts were concentrated and lyophilized and used as primary extracts. Thereafter, 1 L of distilled water was added to the residue of the spirit room, and the mixture was refluxed for 3 hours at about 85 ° C. The extracts were filtered, concentrated and lyophilized using filter paper, which was used as a second hot water extract. Then, the mixture of the first and second hot water extracts was used in the experiment.
1-2. Manufacture of golden extracts
Golden ( Scutellaria baicalensis ), 1 L of 70% ethanol was added, followed by reflux extraction at 60 ° C. for 3 hours. The extract was collected once, and 1 L of 70% ethanol was added thereto. Respectively. After that, the mixture was concentrated under reduced pressure to a final volume of 100 ml using a rotary evaporator, followed by lyophilization and refrigeration.
1-3. Mice immunized with OVA Splenocyte culture
In order to induce allergy to female BALB / c mice at 5 weeks of age, 10 μg of ovalbumin (OVA) and 1 mg of alum were mixed for 30 minutes and then 100 μl of each mouse was weighed every week 2 times (n = 5). One week after the immunization, the mice were sacrificed by cervical dislocation, the spleens were removed from the aseptic state, and transferred to a small petri dish containing RPMI 1640 medium supplemented with 1 ml of the basic medium, i.e., 2-mercaptoethanol and antibiotics. The spleen was then single-celled using a mesh, washed twice with 5 ml of basal medium, and then centrifuged at 1500 rpm for 5 minutes. After removing the supernatant, 1 ml of RBC (red blood cell) lysing buffer (SIGMA R7757) was added and incubated for 3 minutes on ice. 10 ml of basal medium was further added, ≪ / RTI > centrifugation twice.
On the other hand, the 96-well plate was treated with OVA as an antigen at a concentration of 100 μg / ml, and the extract prepared according to the methods of Examples 1-1 and 1-2 was diluted with each concentration, ie, 100 μg / 20 ㎍ / ml), or a mixture of Ganoderma lucidum extract and gold extract was added at a concentration of 100 μg / ml + 20 μg / ml. The mouse spleen cells cultured by the above method were treated at 5 × 10 6 cells / well. After incubation in a CO 2 incubator at 37 ° C for 72 hours, the culture was recovered and the experiment was conducted.
Example 2. Th1 / Th2 Cytokine-modulating activity test
To investigate the effect of Th2 cells on the reduction of immune responses by mixing with the extract of royal jelly and gold extracts, IL-4 BD OptEIATM MOUSE ELISA (enzyme-linked immunosorbent assay) kit and TGF-β kit (R & D Systems) -4 cytokine levels were measured.
To this end, a capture antibody was added to a 96-well plate and incubated overnight at 4 ° C. The plate was coated with antibody, washed with phosphate buffered saline with Tween-20 (PBST) 10% FBS in PBS) was added to each well and reacted at room temperature for 1 hour to perform a blocking process. Next, 100 μl of the standard solution and the culture solution of the mouse spleen cells recovered through the method of Example 1-3 were dispensed into the wells, followed by reaction at room temperature for 2 hours. After the reaction, 100 쨉 l of the secondary antibody conjugated with the IL-4 specific primary antibody capable of detecting IL-4 and streptavidin-Horseradish peroxidase (HRP) was dispensed into each well The reaction was allowed to proceed at room temperature for 1 hour. Then, 100 μl of a substrate solution (0.01% TMB in phosphate-citrate buffer) was added and developed at room temperature for 30 minutes. Then, 50 μl of 2 M H 2 SO 4 was added to each well to stop the color reaction. The absorbance was measured with a microplate reader at.
As a result, as shown in Fig. 1, when the splenocytes were treated with only OVA, the amount of IL-4, which is a cytokine secreted by Th2 cells, was significantly increased to induce an allergic immune response. , The amount of IL-4 was decreased by 21.5% and 15.9%, respectively, and the amount of IL-4 was decreased by 51.1% in the case of treatment with Ganoderma lucidum extract and gold extract .
The results showed that when the royal jelly extract and gold extract were mixed, the Th2 immune response inhibiting activity was significantly enhanced compared to the single treatment of the royal jelly or gold extract.
Example 3. T cell Differentiation inhibition activity test
In order to evaluate T cell differentiation inhibition activity by mixing the mixture of Young's silk extract and gold extract, the culture solution was recovered according to the method of Example 1-3 and then diluted with PBS to a concentration of 2 mg / - (4,5-diethyl thiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT) reagent. After 4 hours, 100 μl of 10% SDS solution was added and allowed to stand overnight. Absorbance was measured at 595 nm using a microplate reader.
As a result, as shown in Fig. 2, when the splenocytes were treated with OVA only, the T cell differentiation was remarkably increased, whereas when the spleen cells or gold extract were treated alone, 3.24%. 16.5%, and 28.4% inhibition of T cell differentiation was observed in the case of treatment with Ganoderma lucidum extract and gold extract.
The above results showed that when the mixture of Ganoderma lucidum extract and Ganoderma lucidum extract was treated, the T cell differentiation inhibitory activity was remarkably enhanced compared to the single treatment of the royal or gold extract.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention. There will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.
Claims (7)
The extract is characterized by being extracted with a solvent selected from the group consisting of water, C 1 to C 4 lower alcohol, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, Lt; / RTI >
Wherein said composition inhibits the production of IL-4.
Wherein said composition inhibits T cell differentiation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150149647A KR101890017B1 (en) | 2015-10-27 | 2015-10-27 | Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150149647A KR101890017B1 (en) | 2015-10-27 | 2015-10-27 | Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170048938A KR20170048938A (en) | 2017-05-10 |
| KR101890017B1 true KR101890017B1 (en) | 2018-08-20 |
Family
ID=58743685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150149647A KR101890017B1 (en) | 2015-10-27 | 2015-10-27 | Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101890017B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102132267B1 (en) * | 2017-08-30 | 2020-07-10 | 한국식품연구원 | Composition for Preventing, Improving or Treating Immune Disease Comprising Fraction of Rosa multiflora extract as an Active Ingredients |
| US11273191B2 (en) * | 2020-03-30 | 2022-03-15 | Script Essentials, Llc | Administering compositions for improved immune system functioning |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101468126B1 (en) * | 2012-12-06 | 2014-12-08 | 한국식품연구원 | Composition for Preventing, Improving or Treating of Ｔｈ2-Mediated Immune Disease Comprising Extracts from Rosa multiflora as an Active Ingredients |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110104625A (en) * | 2010-03-17 | 2011-09-23 | 우석대학교 산학협력단 | Manufacturing method of golden hydrolyzed extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same |
| KR101843574B1 (en) * | 2015-10-27 | 2018-03-30 | 한국식품연구원 | Composition for preventing or treating of Th2-mediated immune disease comprising fermented extracts from Rosa multiflora as an active ingredients |
-
2015
- 2015-10-27 KR KR1020150149647A patent/KR101890017B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101468126B1 (en) * | 2012-12-06 | 2014-12-08 | 한국식품연구원 | Composition for Preventing, Improving or Treating of Ｔｈ2-Mediated Immune Disease Comprising Extracts from Rosa multiflora as an Active Ingredients |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Ethnopharmacology, Vol. 153, No. 3, pp. 667-673 (2014.03.15.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170048938A (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040037909A1 (en) | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | |
| CN107106622B (en) | Composition containing extract or fraction of Acanthaceae plant | |
| KR101874595B1 (en) | Anti-allergic Composition Comprising Herbal Extract fermented by Lactic acid Bacteria as an Active Ingredient | |
| KR20200103564A (en) | Composition comprising extracts of Hizikia fusiforme for anti-inflammation or anti-allergy | |
| KR101252107B1 (en) | Composition for the prevention or treatment of atopic dermatitis containing herbal medicines | |
| KR101843574B1 (en) | Composition for preventing or treating of Th2-mediated immune disease comprising fermented extracts from Rosa multiflora as an active ingredients | |
| KR101890017B1 (en) | Composition for preventing or treating of Th2-mediated immune disease comprising extracts from Rosa multiflora and Scutellaria baicalensis as an active ingredients | |
| KR101732031B1 (en) | Composition for Preventing, Improving or Treating of Allergy Disease Comprising Extracts from Illicium religiosum | |
| KR101756020B1 (en) | Composition for Prevention, Improvement, or Treatment of Atopic Dermatitis Comprising Fermented Extract of Alnus sibirica Fitch. ex Turcz. | |
| KR101843573B1 (en) | Composition for preventing or treating of Th2-mediated immune disease comprising enzyme-treated extracts from Rosae multiflorae Fructus as an active ingredient | |
| KR20170091804A (en) | Composition for treating, improving or preventing allergic disease | |
| KR20200074367A (en) | A composition for improving immunity comprising an effective ingredient of red balloon flower extract having improved safety and immunity improving ability | |
| KR102120758B1 (en) | Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component | |
| KR101838177B1 (en) | Composition for preventing or treating of Th2-mediated immune disease comprising enzyme-treated extracts from Piperis Nigri Fructus as an active ingredients | |
| KR20220082396A (en) | Composition for preventing, ameliorating or treating allergic disease comprising Spatholobus suberectus extract as effective component | |
| KR101838178B1 (en) | Composition for preventing or treating of Th2-mediated immune disease comprising fermented extracts from Piperis Nigri Fructus as an active ingredients | |
| WO2017099413A1 (en) | Composition comprising enzyme-treated rosa multiflora fruit extract as active ingredient for preventing or treating th2-mediated immunological disease | |
| KR102624173B1 (en) | Composition comprising the extract of wild-simulated ginseng and Pyrus ussuriensis for immune-enhancement | |
| KR102204940B1 (en) | Composition for prevention or treatment of atopic dermatitis with Illicium difengpi | |
| KR101707673B1 (en) | Composition for Preventing, Improving or Treating of Allergy Disease Comprising Extracts from Cimicifuga acerina | |
| WO2017074058A1 (en) | Composition containing rosa multiflora fermentation extract as active ingredient for preventing or treating th2-mediated immune diseases | |
| KR20160001805A (en) | Composition for preventing, improving or treating of t h2-mediated immune disease comprising extracts from mollugo pentaphylla, extracts from alisma plantago-aquatica, extracts from eaeocarpus sylvestris or extracts from cimicifuga acerina | |
| KR20240054619A (en) | Composition for preventing, improving or treating atopic dermatitis comprising Juncus leschenaultii extract as effective component | |
| KR20190003415A (en) | Composition for preventing or treating of Th2-mediated immune disease or inflammatory disease comprising enzyme-treated ellagic acid as an active ingredient | |
| KR20190024678A (en) | Composition for preventing or treating of Th2-mediated immune disease comprising miquelianin as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |